Allan Wailoo
Publications and Insights
- Insight: Europe’s pharmaceutical policy choices – And what the United States stands to learn
- Insight: NICE’s new cost-effectiveness threshold: Significance, consequences, and unanswered questions
- Bulletin: Will Europe dance to the tune the US is playing?
- Bulletin: Cost-effectiveness thresholds: Changes, challenges and consequences
- Insight: The Trump Administration’s US Drug Pricing Proposal – What will happen next?
- Insight: Bold politics – what about the economics?: An overview of President Trump’s ‘Most Favoured Nation’ Executive Order
- Publication: Employer Costs from Respiratory Infections
- Insight: Latest estimates show that 20 people a day die in unrelieved pain across the UK at the end of their lives
- Bulletin: Building resilience for critical challenges
- Bulletin: Prevention in women’s health at Parliament
- Publication: The Dynamics of Drug Shortages
- Publication: Innovation for Health System Efficiency and Improvement
- Publication: Reimagining Prevention for a Healthier, More Prosperous Society
- Bulletin: Health economists for a sustainable future
- Bulletin: Is the NHS too brittle for change?
- Publication: Delivering the Triple Win: A Value-Based Approach to Pricing
- Bulletin: Building a resilient and sustainable healthcare in 2023
- Insight: Improving the Measurement of Valued Output in Primary Care in England
- Insight: Estimating the Impact of U.S. Drug Price-setting Policies on Innovation Is Challenging, Even for the Congressional Budget Office
- Publication: Supporting the Era of Green Pharmaceuticals in the UK
- Publication: Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers
- Insight: Does the New CBO Report Change Anything?
- Insight: Due to the Unprecedented Nature of H.R. 3, the CBO Analysis is Unreliable and Can’t Inform Policymaking
- Insight: The CBO Doesn’t Understand Investors
- Insight: H.R. 3 is the Wrong Policy for the Wrong Problem
- Publication: Payment Models for Multi-Indication Therapies
- Publication: The Lower Drug Costs Now Act and Pharmaceutical Innovation
- Publication: Opportunities to Increase Efficiency in Healthcare
- Publication: Delivering the 2.4 Percent: Unlocking UK Pharma R&D Investment through Evidence-Based Policies
- New: Cheap and Dirty: The Effect of Contracting Out Cleaning on Efficiency and Effectiveness
- Publication: Unrelieved Pain in Palliative Care in England
- Publication: Valuing Health at the End of Life: A Stated Preference Discrete Choice Experiment
- Publication: Valuing Health at the End of Life: An Exploratory Preference Elicitation Study